Treatment Options for Recurrent LGSOC

For women with low-grade serous ovarian cancer, recurrence is a reality that many will face. And when it happens, understanding what treatment options are available is essential. In this video, Dr. David M. Gershenson, Professor of Gynecologic Oncology and Reproductive Medicine at MD Anderson Cancer Center, provides an overview of the treatment landscape for recurrent LGSOC, a disease that requires a fundamentally different approach than high-grade ovarian cancer. Treatment for recurrent LGSOC has evolved significantly in recent years. Where chemotherapy alone once dominated the conversation, today's options are broader and more targeted. Secondary surgery, endocrine therapy, CDK4/6 inhibitors, and immunotherapy are all part of a growing toolkit that oncologists can draw from depending on the individual patient's situation. A few things worth understanding as you watch: Endocrine therapy targets the hormonal pathways that drive LGSOC growth and is often a key component of recurrence management CDK4/6 inhibitors represent a newer class of targeted therapy showing promise in LGSOC patients Whether secondary surgery is appropriate depends on a number of individual factors, including where the cancer has returned and how much time has passed since initial treatment Because LGSOC often behaves as a chronic disease, long-term management strategies matter just as much as acute treatment decisions Recurrence is not the end of the road. It's a new chapter that calls for informed, specialized care. Learn more about LGSOC recurrence: https://www.nottheseovaries.org/lgsoc... Learn more about managing LGSOC long term: https://www.nottheseovaries.org/chron... Support ovarian cancer research at Not These Ovaries: https://www.nottheseovaries.org/fund-... #OvarianCancer #LGSOC #LowGradeSerousOvarianCancer #OvarianCancerRecurrence #LGSOCRecurrence #OvarianCancerTreatment #EndocrineTherapy #CDK46Inhibitors #GynecologicCancer #WomensHealth #MDAndersonCancerCenter #NotTheseOvaries